logo VRX


Voraxaze Lowers Plasma Methotrexate (MTX) Levels by ≥97% in 15 Minutes1

At each post-Voraxaze assessment time point, the median MTX concentration was <0.54 μM, corresponding to a median reduction of ≥97% from pre-Voraxaze measurements.2

Voraxaze® (glucarpidase) reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients.1

97% reduction in 15 minutes graph

Reductions in Plasma MTX Concentrations Were Sustained for up to 8 Days1,*

91% (20/22) of patients who received Voraxaze achieved a >95% reduction in plasma MTX concentrations within 15 minutes of administration that lasted for up to 8 days.1

77% (10/13) of patients with MTX levels ≤50 μM who received Voraxaze achieved a reduction of MTX levels to ≤1 μM within 15 minutes of administration that lasted for up to 8 days.1

*Results are from a single-arm, open-label study in 22 treatment-evaluable patients with markedly delayed MTX clearance secondary to acute kidney injury. The primary endpoint of the study was the proportion of patients achieving an MTX plasma concentration of ≤1 μM at 15 minutes that was sustained for up to 8 days following the initial injection.1

Early Administration of Voraxaze May Diminish the Risk for Serious Life-Threatening Toxicity and Even Death3,4

Incidence of Grade 4 toxicity was significantly lower with early administration of Voraxaze.3

77% circle graph
  • Administration of Voraxaze ≤4 days after high-dose methotrexate (HDMTX) exposure appeared to protect from the development of toxicity.3
  • Only 14% (9/64) of patients who received early treatment (within 4 days of HDMTX infusion) with Voraxaze experienced Grade 4 toxicity, compared with 55% (6/11) who received later treatment.3

Incidence of mortality was significantly lower with early administration of Voraxaze.4

Incidence of Mortality Was Significantly Lower With Early Administration of Voraxaze
  • Of 476 patients receiving Voraxaze, death occurred in 22% of patients treated after 4 days following HDMTX infusion compared with 10.9% treated within 2 days of HDMTX infusion.4
  • There are no controlled trials comparing Voraxaze plus supportive care to supportive care measures alone in patients with toxic plasma MTX concentrations due to impaired renal function; therefore, there are no data regarding the effect of Voraxaze on survival or toxic death due to MTX. Voraxaze did not prevent fatal MTX toxicity in 3% of patients in the safety population.1

See How Well Your Patient Is Clearing MTX – Before the Critical Window

MTX Monitoring Tool

Voraxaze Delivered Clinically Important MTX Reductions in Markedly Less Time1,5-7

Treatment with Voraxaze vs standard supportive care alone reduces plasma MTX within 15 minutes vs 11 ± 3 days.1,5-7

Trust Voraxaze for Rapid and Sustained Reductions in MTX1

Not every patient requires Voraxaze, but experts have assembled recommendations to help guide treatment.

Explore guidelines for the use and stocking of Voraxaze so that you’re prepared in an emergency.

Get Guidance